Consensus Opus Genetics, Inc.

Stocks

IRD

US67577R1023

Pharmaceuticals

Real-time Estimate Cboe BZX 06:59:54 29/10/26 am AEDT			5-day change	1st Jan Change
3.685 ^USD	+6.50%		-10.94%	+82.34%

22/10	Opus Genetics, Inc. Announces Transition of Ashwath Jayagopal from Chief Scientific and Development Officer, Effective October 19, 2026	CI
21/10	Opus Genetics Wins FDA Clearance for Childhood Blindness Gene Therapy	MT

Evolution of the Average Target: Opus Genetics, Inc.

Evolution of the Target Price: Opus Genetics, Inc.

Changes in Analyst Recommendations: Opus Genetics, Inc.

17e16d1c281bbf0588513.tCacifftiXtV4PcyH81sI7Dxc9aGm9FAfX6E4yfXKh4._B_V27qYuyFkippZKKkbVp27H4nC9p5zJTfnt2CfR0bSFdqkhNTNMzSRlA~a9fd262ab40eef0c83925e62112811f0

Analysts' recommendations: Opus Genetics, Inc.

10/09	Wedbush Raises Price Target on Opus Genetics to $13 From $10, Keeps Outperform Rating	MT
10/09	Chardan Raises Price Target on Opus Genetics to $16 From $13, Keeps Buy Rating	MT
10/09	Wedbush Raises Opus Genetics Price Target to $13 From $10, Maintains Outperform Rating	MT
07/08	RBC Adjusts PT on Opus Genetics to $9 From $10, Maintains Outperform Speculative Risk Rating	MT
29/07	TD Cowen Initiates Opus Genetics at Buy	MT
18/06	Chardan Raises Price Target on Opus Genetics to $13 From $11, Keeps Buy Rating	MT
04/06	Guggenheim Initiates Opus Genetics at Buy With $16 Price Target	MT
21/05	Leerink Partners Initiates Opus Genetics at Outperform With $10 Price Target	MT
01/05	B. Riley Adjusts Opus Genetics Price Target to $10 From $9, Maintains Buy Rating	MT
30/03	Cantor Fitzgerald Initiates Opus Genetics at Overweight With $15 Price Target	MT
16/03	Oppenheimer Initiates Opus Genetics at Outperform With $10 Price Target	MT
12/03	Wedbush Raises Price Target on Opus Genetics to $10 From $8, Keeps Outperform Rating	MT
12/03	Chardan Raises Price Target on Opus Genetics to $11 From $9, Keeps Buy Rating	MT
11/12	B. Riley Initiates Opus Genetics at Buy With $9 Price Target	MT
21/03/24	Alliance Global Partners Cuts Price Target on Ocuphire Pharma to $20 From $24, Maintains Buy Rating	MT
16/05/23	Cantor Fitzgerald Cuts Ocuphire Pharma's Price Target to $17 From $24, Maintains Overweight Rating	MT
27/01/23	HC Wainwright Adjusts Ocuphire Pharma's Price Target to $20 From $26, Keeps Buy Rating	MT
24/11/21	HC Wainwright Starts Ocuphire Pharma at Buy With $26 Price Target	MT
05/04/21	Ocuphire Pharma : Alliance Global Securities Initiates Coverage on Ocuphire Pharma With Buy Rating, $25 Price Target	MT
29/03/21	Ocuphire Pharma : JonesTrading Starts Ocuphire Pharma at Buy With $20 Price Target	MT
16/03/21	Ocuphire Pharma : Cantor Fitzgerald Adjusts Ocuphire Pharma PT to $20 From $15, Maintains Overweight Rating	MT
11/02/21	Ocuphire Pharma : Canaccord Starts Ocuphire Pharma at Buy with $22 Price Target	MT
20/11/20	Ocuphire Pharma : Cantor Fitzgerald Initiates Ocuphire Pharma at Overweight With $15 Price Target	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	OPUS GENETICS, INC.					+289.32%
	ELI LILLY AND COMPANY					+4.04%
	JOHNSON & JOHNSON					+3.97%
	ABBVIE INC.					-1.12%
	ROCHE HOLDING AG					-3%
	MERCK & CO., INC.					+12.65%
	NOVARTIS AG					-3.77%
	ASTRAZENECA PLC					+23.18%
	AMGEN INC.					-11.3%
	GILEAD SCIENCES, INC.					+0.7%
	Average					+31.47%
	Weighted average by Cap.					+3.08%